论文部分内容阅读
目前临床上使用的中子RBE值3.0,不仅不正确而且是危险的。RBE与光子或中子的每次剂量有关,并且存在织织差异性。不能用单次剂量所得到的RBE转换成分割治疗计划。Hammersmith在对病人和动物实验中确立的4周12次分割,每次130rad的中子RBE值确实是3.0,但这仅是就急性皮肤反应而言。这个值已用于临床,通常用来将适当的光子剂量转换成预计的中子剂量。临床治疗中的每次剂量对于中枢神经系统特别高。用中子治疗的实验资料可以解释使用RBE值3.0的危险性是没有注意到每剂量,组织差异性以及同临床所见的脊髓耐受水平的比较。临床上使用的RBE值通常与可以接受的光子剂量划成坐标图。那么中子的限制
The neutron RBE value of 3.0 currently used clinically is not only incorrect but also dangerous. RBE is related to each dose of photons or neutrons, and weaving dissimilarities exist. The RBE that cannot be obtained with a single dose is converted to a split treatment plan. Hammersmith’s 12-week split of 4 weeks in patient and animal experiments, the 130-rad neutron RBE value was indeed 3.0, but this was only in terms of acute skin reactions. This value has been used clinically and is often used to convert the appropriate photon dose to the expected neutron dose. Each dose in clinical treatment is particularly high for the central nervous system. The experimental data with neutron therapy can explain the risk of using RBE 3.0 without paying attention to the comparison of each dose, tissue variability, and clinically seen spinal cord tolerance. Clinically used RBE values are usually plotted with acceptable photon doses. Then the restriction of neutrons